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Background: Systemic autoinﬂammatory diseases (SAIDs) are rare debilitating disorders of which there is limited
awareness and a signiﬁcant delay in diagnosis. There is no uniform approach in the diagnosis and treatment of
these disorders and the real life state of SAID patient care is poorly characterized. The aim of this study was to
obtain data on the epidemiology, state of care and the perception of physicians who are involved in the care of
SAID patients.
Methods: We performed a questionnaire-based survey and contacted 134 university departments of dermatology,
pediatrics, rheumatology and other SAID departments of tertiary care in German-speaking countries.
Results: A total of 37 departments participated in the survey. The majority of departments managed both adult and
pediatric patients with a variety of monogenic and polygenic/acquired SAIDs. For monogenic SAIDs such as
cryopyrin-associated periodic syndromes (CAPS) and familial Mediterranean fever (FMF), the diagnostic and
treatment strategies were similar among the departments. The diagnostic work-up included inﬂammatory markers
and genetic testing, the ﬁrst line treatment interleukin-1 (IL-1) blockers for CAPS and colchicine for FMF. For
polygenic/acquired SAIDs, we observed a signiﬁcant heterogeneity in diagnostic and therapeutic approaches. As a
major unmet need, diagnostic delay was identiﬁed with a median time to diagnosis of 2 (range 1–5) years. The
overall state of care for SAID patients was rated to be excellent or good by only 12% of departments, and to be
poor or non-sufﬁcient by 40% of departments.
Conclusion: This study demonstrates a high need to improve the state of care and to harmonize diagnostic and
treatment strategies for SAID patients.1Background
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(CAPS),3 whilst in the case of Schnitzler's syndrome (SchS), there are only
around 300 cases reported in the literature.4 Familial Mediterranean
fever (FMF) shows a somewhat higher prevalence (1–2 per 1000) in
Eastern Mediterranean countries, but presents with low frequencies in
other geographic regions (e.g. 48 per 1 million children in Germany).5–7
The Eurofever registry (printo.it/eurofever), the largest international
epidemiologic data collection of SAIDs, recently listed a total number of
1880 conﬁrmed patients not including systemic juvenile idiopathic
arthritis (SJIA) and other polygenic/acquired SAIDs.8 AID-Net, a trans-
lational research network and registry for SAID patients in Germany,
recorded 117 monogenic SAID patients during the ﬁrst 9 months after
initiation of the project.9
SAIDs are debilitating disorders of which there is limited awareness, a
signiﬁcant delay in diagnosis and high rates of misdiagnoses.8 These
obstacles result in insufﬁcient treatment, marked quality of life impair-
ment, high morbidity and eventually mortality in a large proportion of
patients.10
Despite the recent development of clinical diagnostic criteria for
selected SAIDs,3 there are still major challenges including atypical or
overlapping phenotypes as well as phenotypically clear cases with
mutation-negative status.11 In addition, for many SAIDs approved
treatment options are still lacking.12 Overall, the real life state of SAID
patient care remains poorly characterized.
To address these gaps of knowledge and to provide information on
management and perception (e.g. expenditure of time and costs and
patient characteristics that might affect care) of SAID patients by their
treating physicians, we initiated a survey-based study on the state of care
in German-speaking countries. The main objective of this study was to
obtain data on: (i) the epidemiology of SAID patients seen at departments
of tertiary care, (ii) the diagnostic and (iii) therapeutic approaches used
in clinical practice, and (iv) the problems and unmet needs in the man-
agement of SAIDs.
Methods
Study design and participating departments
This cross-sectional study was conducted between April 2014 and
March 2016. In the ﬁrst step, we identiﬁed potential German-speaking
departments of tertiary care for SAID patient care in Germany, Austria
and Switzerland. This included the review of published lists of all
university-based departments of dermatology, pediatrics and rheuma-
tology in these countries as well as the identiﬁcation of further non-
university departments of tertiary care from the published list of the
German Society of Rheumatology. In total, the respective heads of 134
departments (meaning one physician per department) were asked for
their interest in participating in this study and were provided a letter of
information and invitation by mail.
Questionnaire development
The questionnaire was developed after a thorough literature review
by SAID experts, including rheumatologists, pediatricians and derma-
tologists. The ﬁnal questionnaire consisted of 39 questions with Likert
scale answer options, quantitative questions, yes/no lists and additional
free text [See Additional File 1].
The questionnaire was divided into 6 different sections: (i) general
data on the participating clinic and/or department; (ii) general questions
on SAID patients and patient characteristics; (iii) questions on the diag-
nostic work up; (iv) questions on the therapeutic approach; (v) general
questions on the current state of SAID patient care; and (vi) questions
regarding the need for guidelines in SAID patient care.
The following 11 diseases were assessed: CAPS, FMF, Hyper IgD
syndrome (HIDS)/Mevalonate kinase deﬁciency (MKD), TNF-receptor-
associated periodic syndrome (TRAPS), Pyogenic arthritis pyoderma2gangrenosum and acne syndrome (PAPA), Chronic recurrent osteomye-
litis (CRMO), SchS, Adult-onset Still's disease (AOSD), SJIA, Pyoderma
gangrenosum (PG), and Behcet's disease (BD).
Statistical analysis
All data from the completed paper survey questionnaires were
transferred to an electronic databank (IBM SPSS Statistics version 23).
For statistical analysis, descriptive measures (mean with standard devi-
ation, median with the ﬁrst and third quartile range, proportions) were
applied as appropriate, and graphical representations and a table were
employed to summarize the data. There were only few missing data
observed in the completed questionnaires. These were not replaced.
Results
Participating departments
Of the 134 invited departments, 37 were interested in participating
and returned the completed questionnaire, whereas 18 rejected partici-
pation due to lack of interest or lack of experience in managing these
patients. Seventy-nine departments did not reply for unknown reasons. In
case of non-reply, all departments were contacted at least two times by
mail.
Of the received questionnaires, 13 were from dermatology, 13 from
pediatric and 11 from rheumatology departments. The majority of de-
partments (n ¼ 31; 83.8%) were located in Germany, 3 departments
(8.1%) were in Austria and 3 (8.1%) were in Switzerland. Nearly all
participating departments (n ¼ 35; 94.6%) belonged to university hos-
pitals. The mean number of hospital beds in the respective departments
was 58.9  44.2. In 9 hospitals, different disciplines (meaning more than
one department) participated in the survey.
Dermatologists, pediatricians and rheumatologists manage different SAIDs
The median number of patients seen per department within the last
12 months of the observation period was highest for FMF, followed by
SJIA and BD. The lowest number of patients was observed for HIDS.
Monogenic SAIDs as well as CRMO and SJIA were primarily seen by
pediatricians. Dermatologists usually took care of PG and SchS patients
and rheumatologists particularly looked after BD and AOSD patients
[Table 1]. Interdisciplinary patient care was frequently implemented for
SAIDs such as BD, SchS and PAPA syndrome (86.2%, 78.3% and 75% of
departments respectively). The youngest age of onset was reported for
HIDS patients and the oldest age for PG patients. Of note, female gender
was predominant in all SAIDs [Table 1].
SAIDs are associated with delay in diagnosis
The median time to diagnosis showed great intra-individual vari-
ability and differed between the diseases as well. The median time to
diagnosis for all SAIDs was 2 (interquartile range 1–5) years and 5
(interquartile range 1.9–6.3) years vs. 1 (interquartile range 0.5–3) year
for monogenic SAIDs and polygenic/acquired SAIDs, respectively. The
highest diagnostic delay was observed in TRAPS, CAPS, HIDS and SchS
with a median of 5–6 years [Fig. 1].
Inﬂammation markers and genetic testing are common diagnostic tools in
the work-up of SAID patients
Complete blood count (CBC) and C-reactive protein (CRP) were
performed in almost all patients with suspected or known SAIDs. Serum
amyloid A (SAA) was determined more frequently in monogenic than
polygenic/acquired SAIDs (60.1% vs. 29.4%). SAA and S100A12 or S100
A8/9 levels were studied particularly in SJIA (39.1% and 41.7%) and
performed most frequently by pediatricians [Figs. 2A and 3]. Thirty-ﬁve
Table 1
Epidemiology of selected SAIDs as reported by the participating departments.
SAID median number of patients seen within the last 12 months median age of onset (years) mean percentages for females
by all disciplines by pediatricians by dermatologists by rheumatologists
CAPS 2 (1–3.75) 2 (1–3.5) 1 (0.5–3) 3 (1–4) 20 (10–30) 64.7  28.8
FMF 10 (3–20) 20 (10–52) 2 (0.5–5) 6 (3–13) 14.5 (10–29.75) 56.3  28.9
HIDS/MKD 0 (0–1) 1 (0–2) 0 (0–0.75) 0 (0–1) 8 (2–24) 61.1  48.6
TRAPS 1 (1–2) 1.5 (0.75–2.25) 1 (0–1.5) 1 (1–1.75) 18 (6.5–32.5) 64.4  44.6
PAPA 1 (0–2) 2 (0–6) 1.5 (0–2.25) 0 (0–1) 25 (7–36.25) 56.5  36.9
CRMO 4.5 (1.75–15) 15 (4.5–20) 0 (0–4.5) 3 (2–4.75) 12 (10–26) 72.8  20.2
SchS 1 (0–2) 0 (0–0) 2 (1–3) 1 (0–1) 50 (40–50) 52.4  40.0
AOSD 4 (0.75–10) 0 (0–2.5) 1 (1–4) 10 (6–15) 31.5 (24.75–40) 73.3  19.1
SJIA 5 (2–12) 12 (2–20) 5 (0.5–9) 5 (2–7) 9 (6.25–12) 62.3  25.7
PG 3 (0–10.5) 0 (0–0.25) 12 (4–20) 2 (0–4) 55 (40–60) 60.7  25.4
BD 5 (1–10) 1 (0.5–2) 5 (2–10) 10 (4–15) 30 (15–35) 53.6  34.2
Fig. 1. Time to diagnosis. The participating departments were asked to rate the time from the start of ﬁrst symptoms to the ﬁnal diagnosis for the different diseases.
The bars represent the median time to diagnosis in years with interquartile ranges.
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testing in the diagnostic work-up of patients. Genetic testing was done in
suspected monogenic SAIDs namely, HIDS, TRAPS, FMF, CAPS and PAPA
[Fig. 2B]. Pediatricians (63.1%) most frequently requested genetic ana-
lyses followed by rheumatologists (43.3%) and dermatologists (31.8%)
[Fig. 3]. Thirteen (39.4%) participating departments experienced ob-
stacles in performing genetic analyses, with high costs being the most
common reported issue. In addition, a lack in speciﬁcity or sensitivity of
the methods (e.g. detection of genetic polymorphisms or non-detection of
genetic mosaicisms) leading to over- or underdiagnosis was mentioned.
Serum ferritin, a biomarker for disease activity in SJIA and AOSD, and
serum immune ﬁxation, indicated in SchS to detect paraproteins that
conﬁrm the diagnosis, were also included in the diagnostic part of the
questionnaire.13,14 In our study, ferritin levels were primarily analyzed
by rheumatologists and pediatricians (69.2% and 66.3%) in cases of
suspected or conﬁrmed AOSD, SJIA and CAPS. Immune ﬁxation was
particularly evaluated in suspected cases of SchS (63.2%) and by der-
matologists (50%) in this survey [Figs. 2B and 3].
Skin biopsies are commonly performed by dermatologists
Patients with SAIDs presenting at the skin (e.g. urticarial, pustular or
ulcerative lesions) often show neutrophil-rich dermal inﬁltrates upon
skin biopsy. Although these ﬁndings are non-speciﬁc, they may guide the
differential diagnosis and exclude other diseases with similar cutaneous
phenotype.15,16 Dermatologists performed this procedure most3frequently (59.3%), followed by rheumatologists (13.9%) and pediatri-
cians (1.2%). Skin biopsies were commonly performed, if SchS or PG
were suspected [Figs. 2B and 3].
A variety of tools are used to assess SAID disease activity
All three disciplines emphasized the importance of history taking,
physical examination data, laboratory parameters (CRP, ferritin, SAA
etc.), imaging and/or photo records to assess disease activity in SAID
patients. However, there was great heterogeneity in the use of clinical
scores. Dermatologists reported monitoring of disease activity primarily
by general quality measures such as the Physician Global Assessment
(PGA) and Visual Analog Scale (VAS). Pediatricians referred to the Auto-
Inﬂammatory Diseases Activity Index (AIDAI), Childhood Health
Assessment Questionnaire (CHAQ), American College of Rheumatology
(ACR) Pediatric score, Disease Activity Score 28 (DAS28), Juvenile
Arthritis Disease Activity Score (JADAS) and also PGA and VAS. Rheu-
matologists reported the use of AIDAI, DAS28 and Birmingham vasculitis
activity score (BVAS).
Non-speciﬁc clinical symptoms and lack of diagnostic criteria are challenges
in diagnosing SAIDs
The top three reported difﬁculties and challenges in the diagnostic
approach of SAIDs were: (1) atypical or no obvious clinical symptoms at
presentation; (2) difﬁculties in differentiating from other entities because
Fig. 2. Diagnostic approach. The participating departments were asked for their
diagnostic approach in patients with suspected SAIDs. Participating departments
had to pick all applicable diagnostic measures for the different SAIDs. The re-
sults are expressed as the proportion of departments that chose the different
diagnostic parameters. CBC: Complete blood count; CRP: C-reactive protein;
SAA: Serum amyloid A; S100A12: S100 calcium-binding protein A12.
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selected diseases. Further problems were the unavailability of full panel
laboratory services as well as ﬁnancial restrictions reported by some
departments, which hampered the performance of expensive diagnostic
tests such as genetic analyses.Glucocorticoids are commonly used in selected SAIDs
At the time of the survey study, approved treatment options, namely
cytokine blockade, were available for CAPS (anti-IL-1) and SJIA (anti-IL-
1/anti-IL-6) patients. In agreement with the existing guidelines, gluco-
corticoids were perceived as the ﬁrst line treatment in several SAIDs by
the majority of departments. The most frequently reported diseases,
which were initially treated with glucocorticoids, according to the par-
ticipants' responses, included PG (66.7%), SJIA (62.5%) and CRMO
(52.9% of departments) [Fig. 4].IL-1 blockers are perceived as ﬁrst line treatment for CAPS by most
departments
The IL-1 receptor antagonist anakinra was reportedly used as ﬁrst-line
treatment in monogenic SAIDs, especially in CAPS followed by HIDS and
TRAPS (52%, 35.7% and 33.3% of departments). Conversely, anakinra
was rarely used as ﬁrst-line therapy in polygenic/acquired diseases4except in SchS (50% of departments), whereas canakinumab, a fully
human monoclonal antibody to IL-1β, was prescribed as ﬁrst-line medi-
cation only in CAPS and SchS (29.2% and 11.8% of departments). Tumor
necrosis factor (TNF) blockers were considered as ﬁrst choice in TRAPS,
PAPA, SJIA and AOSD (33.3%, 17.6%, 8.3% and 5% of departments).
Lastly, tocilizumab was regarded as ﬁrst-line therapy only in SchS and by
very few physicians (11.8% of departments).
Other reported ﬁrst-line treatments included colchicine, which was
the drug of choice for FMF and BD (96.4% and 38.5% of departments).
Also, non-steroidal anti-inﬂammatory drugs (NSAIDs) in HIDS and
CRMO,methotrexate in AOSD, CRMO and SJIA as well as ciclosporin A in
PG and azathioprine in BD and PG were named [Fig. 4].
SAID patient care is often evaluated as poor and insufﬁcient
The general state of care for SAID patients was rated to be excellent or
good by only 11.5% of departments, satisfying or sufﬁcient by 48.5% and
to be poor or non-sufﬁcient by 40% of departments.
The participating departments were asked to compare the general
conditions in SAID patient care with the situation of their other pa-
tients. Notably, the expenditure of time was reported to be above
average by 80.6%. The drug and laboratory costs in managing SAIDs
were noted to be more expensive compared with other diseases by
91.7% and 75.0% of departments, respectively. In contrast, the fre-
quency of follow-up visits was in an average range by the majority of
departments (70.3%). In a further set of questions, the participating
departments were asked for characteristics of SAID patients that might
affect care. Interestingly, 36% of departments regarded patient guid-
ance to be difﬁcult. However, none reported a poor patient compliance
and only a single department stated that the patients seemed unsatis-
ﬁed with the current treatment (2.9%). Half of the departments
perceived problems with organizing interdisciplinary patient care and
communication between the disciplines. In addition, 60% of de-
partments indicated problems in the treatment of SAID patients. Here,
the reimbursement for biologics, particularly in cases with off-label
use, was the main issue of concern.
Guidelines for SAID patient care are essential
There were only few existing guidelines regarding the management of
selected SAIDs, namely FMF, SJIA, PG and BD when this survey was
conducted.17–22 The majority of departments (83.5%) saw a need for
guideline development in all SAIDs. Among them, AOSD was the most
frequently stated (95%), followed by CRMO (91.7%) and PAPA syn-
drome (87.5%). A need for optimization of existing guidelines was stated
by more than half (59.3%) of the participating departments. The diseases
named most often were CRMO (71.4%), followed by HIDS (66.7%) and
CAPS (64.3%).
Discussion
Systematic research in SAIDs represents a major challenge due to the
rarity of the diseases. Thanks to the implementation of two European
registries, EUROFEVER and AID-Net, essential data on the epidemiology,
clinical presentation and treatment responses in SAIDs were obtained.8,9
With this study, we provide further data on the real-life state of care and
unmet needs in managing SAID patients.
Our ﬁndings emphasize the rarity of SAIDs even in departments of
tertiary care and showed that most participating departments managed a
variety of different autoinﬂammatory diseases and patients. Among he-
reditary monogenic SAIDs, FMF was the most prevalent disease, whereas
the least one was HIDS. This was concordant to the data of previously
published studies derived from the EUROFEVER registry.8,12 Interest-
ingly, the female predominance in this study was higher than previously
reported in the EUROFEVER registry. The reason for this discrepancy
remains unclear. It may be speculated that the higher number of females
Fig. 3. Diagnostic measures distributed by each discipline. The participating departments were asked for their diagnostic approach in patients with suspected SAIDs.
Participating departments had to pick diagnostic measures for the different SAIDs. The results are expressed as the proportion of departments distributed by each
discipline that chose the different diagnostic parameters.
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care as compared to men. Also, geographic differences in gender pre-
dominance may play a role as the majority of patients included in the
EUROFEVER registry were derived from Italy. As expected, of all disci-
plines, pediatricians were the ones primarily involved in managing
monogenic SAIDs, while all three disciplines, i.e., dermatologists, pedi-
atricians and rheumatologists, contributed to the management of certain
polygenic/acquired SAIDs.Fig. 4. First line treatment choices. The participating departments were asked for the
the top 3 ﬁrst line treatment options in different SAIDs reported by the departments
5The diagnostic delay caused by limited disease awareness is known to
be a major issue in SAID management. This was conﬁrmed by our survey.
Consistent with earlier reports, the diagnostic delay was usually longer in
monogenic than polygenic/acquired diseases,8 and the median time to
diagnosis was slightly reduced (e.g. 5 years in this study vs. 7.3 years for
monogenic SAIDs in previous reports).8 Diagnostic delay is known to
result in quality of life impairment and long-term sequelae such as sec-
ondary amyloidosis.10 Thus, our study underlines the high need toir treatment of ﬁrst choice for patients with the different SAIDs. The results show
. * Four treatment options are shown because of equal frequency.
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time to diagnosis of hereditary monogenic SAIDs was demonstrated over
the last decade; e.g. patients who were born after the year 2000 had less
diagnostic delay compared to those who were born before the 1970s,8
which may be explained by improved availability and better access to
genetic analyses together with a wider recognition of these conditions.
Provisional classiﬁcation criteria were recently proposed to pre-select
potential patients eligible for genetic analyses and/or to classify pa-
tients with suspected autoinﬂammatory periodic fever diseases.11 These
will help to reduce diagnostic delay and enable proper treatment for
future SAID patients.
There was overall agreement between departments to use laboratory
inﬂammation markers such as CBC and CRP on a routine basis. Notably,
the use of genetic analyses to conﬁrm a diagnosis of monogenic SAID was
reported by nearly all departments (94.3%), although the availability,
high costs and interpretation of genetic tests were acknowledged as
critical drawbacks by many of them. We did not ask for genetic test re-
sults as this would require individual patient data and we were particu-
larly interested in learning which diagnostic and management tools were
used. During recent years, reports on atypical clinical phenotypes and the
increased use of genetic tests resulted in reports of genetic variants or
polymorphisms (e.g. the R92Q variant in TRAPS or V198 M in CAPS), for
which their clinical relevance often remained unclear. Current efforts to
analyze genotype-phenotype associations from large databases such as
the EUROFEVER registry may contribute to better guide diagnosis and
treatment decisions in hereditary SAIDs.23–26
Disease activity in SAID patients varies considerably. Besides inter-
individual differences, there are also intra-individual changes, e.g.
higher disease activity in winter as compared to summer time. As vari-
ations in disease activity may require treatment changes, the assessment
of disease activity should be embedded in the clinical routine. The
participating departments reported the use of various clinical assessment
tools. This largely reﬂects the current situation that there is no consensus
on how to evaluate and monitor disease activity in SAID patients. So far,
few disease-speciﬁc activity scores were developed, namely the auto-
inﬂammatory diseases activity index (AIDAI) in hereditary recurrent
fever syndromes,27 Schnitzler Activity Score (SchAS) in SchS28 and Ju-
venile Arthritis Disease Activity Score (JADAS) in SJIA29 and
Muckle-Wells-syndrome disease activity score (MWS-DAS) in MWS.30
Due to the limited patient numbers, validation of these tools remains a
major challenge. Another issue in SAIDs is organ damage such as hearing
loss or kidney failure because of secondary amyloidosis. Organ damage is
not captured by assessing disease activity, and it often develops as a
consequence of diagnostic delay. To address this, the autoinﬂammatory
disease damage index (ADDI)31 was recently established. Also, attempts
to create speciﬁc health-related quality of life instruments in SAIDs such
as the juvenile auto-inﬂammatory disease multidimensional assessment
report (JAIMAR)32 have to be acknowledged. Further development and
harmonization of SAID-speciﬁc clinical assessment tools will be impor-
tant to improve patient care and future research in this ﬁeld.
Licensed treatment options for SAIDs were limited at the time of this
study and still are, although recently the use of canakinumab has been
approved for FMF, TRAPS and HIDS.33 Hence, the therapeutic ap-
proaches used by participating departments showed substantial hetero-
geneity. Interestingly, glucocorticoids remained within the top three ﬁrst
line therapies in all SAIDs, except FMF. The abundant use of glucocor-
ticoids may be explained by 1) the existing guideline recommendations;
2) the overall availability and great experience with glucocorticoids
comparing to other treatment options and 3) the limited access to drugs
such as cytokine blockers in off-label indications as well as iv) cases in
which treatment was started before the diagnosis was conﬁrmed. The use
of IL-1 blockers, in particular anakinra, as ﬁrst choice treatment reported
by the majority of departments in CAPS, HIDS, TRAPS and SchS is
mirrored by the efﬁcacy of these drugs in clinical trials34,35 and available
data from the EUROFEVER registry.12 In FMF, although not approved,
there was wide consensus among the participating physicians to use6colchicine as ﬁrst line treatment. This was afﬁrmed by multiple lines of
evidence showing a beneﬁt of colchicine in FMF treatment.12,36–38
In general, the data from our study on treatment decisions demon-
strate the common use of off-label therapies in SAIDs and emphasize the
need for management guidelines. Lately, several initiatives started to
implement practical management guidelines for speciﬁc SAIDs such as
CAPS, FMF, HIDS, TRAPS and SJIA/AOSD,34,39–45 and further efforts to
optimize existing guidelines are currently ongoing. Nonetheless, the
rarity of the diseases and limited data from large scale, randomized
controlled trials remain major challenges within this task.34,46
There were some limitations of our study. First, there was a selection
bias of participants, who were recruited from departments of Derma-
tology, Pediatrics and Rheumatology, whereas other disciplines were not
involved. Although the included disciplines focused on different diseases,
it cannot be excluded that single patient numbers were reported by
more than one department. Furthermore, only German-speaking de-
partments were involved, so the data may not be representative of other
countries. Novel emerging SAIDs such as NOD2-associated auto-
inﬂammatory disease (Yao syndrome)47,48 or less common
disorders including NLRP12-associated autoinﬂammatory disease49 and
proteasome-associated autoinﬂammatory syndrome (PRAAS)50 have not
been included in this study. Also, the retrospective study design and data
obtained relied on the estimations by the participating physicians, which
may have produced inaccuracies. Finally, the results should be inter-
preted with care as only 28% of the departments invited participated
actively in this survey, suggesting that non-participating institutions may
be less experienced in treating SAID patients. However, comparing this
response rate to other questionnaire-based surveys in much more com-
mon diseases, such as urticaria in which responses lay between 9%51 and
40%,52 the return rate in our study involving rare diseases was consid-
ered acceptable.
Conclusion
We observed great heterogeneity in the diagnostic work-up and
treatment of SAIDs, especially in polygenic/acquired SAIDs. Our project
demonstrates a high need to improve the real-life state of care by
harmonizing diagnostic and treatment strategies for SAID patients.
Specialized departments with interdisciplinary care and the close
collaboration with international SAID registries may contribute to opti-
mize the future state of care for these patients.
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